Mesoblast (MESO)

$11.05

+0.02

(+0.18%)▲

Market is closed - opens 8 PM, 27 Nov 2024

Performance

  • $10.76
    $11.10
    $11.05
    downward going graph

    2.62%

    Downside

    Day's Volatility :3.06%

    Upside

    0.45%

    downward going graph
  • $1.61
    $12.18
    $11.05
    downward going graph

    85.43%

    Downside

    52 Weeks Volatility :86.78%

    Upside

    9.27%

    downward going graph

Returns

PeriodMesoblastSector (Health Care)Index (Russel 2000)
3 Months
69.69%
-6.4%
0.0%
6 Months
29.46%
0.7%
0.0%
1 Year
302.55%
10.9%
0.0%
3 Years
-10.9%
10.2%
-21.2%

Highlights

Market Capitalization
1.1B
Book Value
$0.42
Earnings Per Share (EPS)
-1.05
PEG Ratio
0.0
Wall Street Target Price
14.5
Profit Margin
0.0%
Operating Margin TTM
-1248.53%
Return On Assets TTM
-5.41%
Return On Equity TTM
-17.91%
Revenue TTM
5.9M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-41.199999999999996%
Gross Profit TTM
-47.4M
EBITDA
-56.1M
Diluted Eps TTM
-1.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-0.78
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Mesoblast(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 31.22%

Current $11.05
Target $14.50

Company Financials

FY19Y/Y Change
Revenue
16.7M
↓ 3.57%
Net Income
-89.8M
↑ 154.46%
Net Profit Margin
-537.01%
↓ 333.5%
FY20Y/Y Change
Revenue
32.2M
↑ 92.3%
Net Income
-77.9M
↓ 13.21%
Net Profit Margin
-242.38%
↑ 294.63%
FY21Y/Y Change
Revenue
7.5M
↓ 76.81%
Net Income
-98.8M
↑ 26.78%
Net Profit Margin
-1.3K%
↓ 1082.87%
FY22Y/Y Change
Revenue
10.2M
↑ 36.95%
Net Income
-91.3M
↓ 7.55%
Net Profit Margin
-894.59%
↑ 430.66%
FY23Y/Y Change
Revenue
7.5M
↓ 26.54%
Net Income
-81.9M
↓ 10.35%
Net Profit Margin
-1.1K%
↓ 197.12%
FY24Y/Y Change
Revenue
5.9M
↓ 21.32%
Net Income
-88.0M
↑ 7.41%
Net Profit Margin
-1.5K%
↓ 398.56%
Q2 FY22Q/Q Change
Revenue
2.2M
↑ 10.59%
Net Income
-21.5M
↑ 0.72%
Net Profit Margin
-964.7%
↑ 94.57%
Q3 FY22Q/Q Change
Revenue
1.4M
↓ 35.12%
Net Income
-16.9M
↓ 21.31%
Net Profit Margin
-1.2K%
↓ 205.36%
Q4 FY22Q/Q Change
Revenue
2.0M
↑ 37.21%
Net Income
-24.5M
↑ 45.02%
Net Profit Margin
-1.2K%
↓ 66.61%
Q1 FY23Q/Q Change
Revenue
2.1M
↑ 8.03%
Net Income
-21.9M
↓ 10.48%
Net Profit Margin
-1.0K%
↑ 211.94%
Q2 FY23Q/Q Change
Revenue
1.7M
↓ 20.8%
Net Income
-16.3M
↓ 25.77%
Net Profit Margin
-960.42%
↑ 64.31%
Q4 FY23Q/Q Change
Revenue
1.7M
↑ 0.0%
Net Income
-16.3M
↑ 0.0%
Net Profit Margin
-960.42%
↑ 0.0%
FY19Y/Y Change
Total Assets
652.1M
↓ 5.82%
Total Liabilities
171.1M
↑ 16.82%
FY20Y/Y Change
Total Assets
733.6M
↑ 12.5%
Total Liabilities
184.3M
↑ 7.72%
FY21Y/Y Change
Total Assets
744.7M
↑ 1.52%
Total Liabilities
163.3M
↓ 11.37%
FY22Y/Y Change
Total Assets
662.1M
↓ 11.09%
Total Liabilities
165.1M
↑ 1.09%
FY23Y/Y Change
Total Assets
669.4M
↑ 1.1%
Total Liabilities
167.6M
↑ 1.5%
FY24Y/Y Change
Total Assets
669.2M
↓ 0.04%
Total Liabilities
188.8M
↑ 12.66%
Q3 FY22Q/Q Change
Total Assets
684.5M
↑ 3.38%
Total Liabilities
161.7M
↓ 2.06%
Q4 FY22Q/Q Change
Total Assets
668.1M
↓ 2.4%
Total Liabilities
168.1M
↑ 3.94%
Q1 FY23Q/Q Change
Total Assets
669.4M
↑ 0.2%
Total Liabilities
167.6M
↓ 0.29%
Q2 FY23Q/Q Change
Total Assets
670.3M
↑ 0.13%
Total Liabilities
161.6M
↓ 3.59%
Q4 FY23Q/Q Change
Total Assets
670.3M
↑ 0.0%
Total Liabilities
161.6M
↑ 0.0%
Q2 FY24Q/Q Change
Total Assets
669.2M
↓ 0.17%
Total Liabilities
188.8M
↑ 16.86%
FY19Y/Y Change
Operating Cash Flow
-57.8M
↓ 22.96%
Investing Cash Flow
-1000.0K
↓ 13.27%
Financing Cash Flow
71.6M
↑ 4.37%
FY20Y/Y Change
Operating Cash Flow
-56.4M
↓ 2.47%
Investing Cash Flow
-3.3M
↑ 227.3%
Financing Cash Flow
137.0M
↑ 91.38%
FY21Y/Y Change
Operating Cash Flow
-106.7M
↑ 89.27%
Investing Cash Flow
-1.6M
↓ 49.68%
Financing Cash Flow
114.5M
↓ 16.48%
FY22Y/Y Change
Operating Cash Flow
-65.8M
↓ 38.34%
Investing Cash Flow
-232.0K
↓ 85.91%
Financing Cash Flow
-9.9M
↓ 108.62%
FY23Y/Y Change
Operating Cash Flow
-63.3M
↓ 3.82%
Investing Cash Flow
-194.0K
↓ 16.38%
Financing Cash Flow
74.5M
↓ 854.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.3M
↓ 1.07%
Investing Cash Flow
16.0K
↓ 147.06%
Financing Cash Flow
38.8M
↓ 2026.29%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.2M
↓ 12.5%
Investing Cash Flow
16.0K
↑ 0.0%
Financing Cash Flow
-3.2M
↓ 108.3%

Technicals Summary

Sell

Neutral

Buy

Mesoblast is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mesoblast
Mesoblast
21.08%
29.46%
302.55%
-10.9%
-12.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.29%
-22.98%
-6.09%
16.5%
106.01%
Biontech Se
Biontech Se
6.62%
28.33%
24.67%
-65.3%
465.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-12.52%
67.25%
57.65%
33.12%
110.8%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.08%
3.32%
31.85%
151.49%
110.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mesoblast
Mesoblast
0.12
NA
0.0
0.0
-0.18
-0.05
NA
0.42
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mesoblast
Mesoblast
Buy
$1.1B
-12.32%
0.12
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
106.01%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
465.36%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
110.8%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.1B
110.78%
32.84
-4.51%

Insights on Mesoblast

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.13M → 1.69M (in $), with an average decrease of 10.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -24.48M → -16.26M (in $), with an average increase of 15.5% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 44.0%

Institutional Holdings

  • Group One Trading, LP

    0.20%

  • Morgan Stanley - Brokerage Accounts

    0.15%

  • Summit X, LLC

    0.13%

  • Penbrook Management LLC

    0.09%

  • Prosperity Wealth Management Inc

    0.08%

  • Marshall Wace Asset Management Ltd

    0.07%

Company Information

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf

Organization
Mesoblast
Employees
73
CEO
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Industry
Health Technology

FAQs